How Female Sex Affects Cognitive Health and Dementia Risk

Women represent approximately 65% of all Alzheimer's cases in the United States, and their lifetime risk of developing Alzheimer's disease is roughly 1 in 5, compared to approximately 1 in 10 for men. For decades, this disparity was attributed almost entirely to longevity — women live longer, and age is the dominant risk factor. However, more recent research has established that longevity does not fully explain the gap.

A key insight from the Alzheimer's Disease Neuroimaging Initiative and other longitudinal studies is that women carrying the APOE4 gene variant appear to have a larger risk increase from that variant than men do. APOE4 roughly doubles late-onset Alzheimer's risk in men, but increases risk by three to four times in women. The interaction between estrogen signaling and APOE4 is one of the most active areas of current Alzheimer's research.

The menopausal transition — and the sharp decline in estrogen that accompanies it — is increasingly recognized as a critical window for brain health. Estrogen has neuroprotective effects: it promotes glucose metabolism in the brain, reduces neuroinflammation, and supports synaptic plasticity. The abrupt estrogen decline of perimenopause and menopause may remove these protective effects at a vulnerable developmental stage for Alzheimer's pathology.

Research on healthy aging consistently finds that women outperform men on verbal memory tasks across adulthood — which may actually make early Alzheimer's harder to detect in women on standard clinical tests, because women start from a higher baseline and can mask equivalent pathological change with residual verbal strength.

Visuospatial processing and processing speed show less consistent sex differences in healthy aging but appear to be affected somewhat differently in the context of Alzheimer's pathology. For individual monitoring purposes, the most important domains to track are the same across sexes: episodic memory, processing speed, and semantic fluency.

The perimenopause and early menopause period — typically the late 40s to early 50s — is emerging in research as a meaningful window for brain health intervention. Regular aerobic exercise, sleep quality optimization, and cardiovascular risk management are all especially relevant during this transition. The effect of hormone therapy on dementia risk remains an area of active research with complex, evolving findings that are worth discussing with a menopause specialist.

For women with the APOE4 gene variant, the combination of female sex and APOE4 represents a significantly elevated risk picture compared to either factor alone. This is a specific reason to be proactive about both lifestyle factors and cognitive monitoring from midlife onward.

The standard evidence-backed prevention strategies — exercise, sleep, social and cognitive engagement, cardiovascular health management — are fully applicable and arguably especially important for women given the elevated risk. None of these require a specific genetic profile to begin.

For women, the perimenopause period often involves genuine cognitive symptoms — brain fog, word-finding difficulty, memory lapses — that may be hormonally driven rather than pathological. This creates a specific challenge: how to distinguish normal hormonal cognitive effects from early Alzheimer's pathology. An objective longitudinal baseline established before or during perimenopause provides exactly the comparison needed.

If cognitive performance dips during perimenopause and recovers, the trend data reflects that. If it dips and keeps declining, that is a different signal. Keel provides the continuous objective trend line that converts an inherently confusing symptomatic experience into interpretable data — enabling informed discussion with a physician rather than anxious self-assessment.